Martin Treder
Fundador en LTZ Therapeutics, Inc. .
Perfil
Martin Treder founded U3 Pharma AG in 2001 and CT Atlantic Ltd.
in 2008, where he held the title of Research Director and Chief Scientific Officer, respectively.
Dr. Treder is also the founder of LTZ Therapeutics, Inc. He served as the Chief Scientific Officer at Affimed NV from 2015 to 2019.
Dr. Treder received his undergraduate degree from Monash University and his doctorate from Technische Universität München.
Cargos activos de Martin Treder
| Empresas | Cargo | Inicio |
|---|---|---|
LTZ Therapeutics, Inc.
 LTZ Therapeutics, Inc. BiotechnologyHealth Technology LTZ Therapeutics, Inc. is an American immunotherapy-focused biotech company that develops novel therapies. The company was founded by Jianhui Zhou, Robert Li, and Martin Treder, with Robert Li serving as the CEO since incorporation. | Fundador | - |
Antiguos cargos conocidos de Martin Treder.
| Empresas | Cargo | Fin |
|---|---|---|
| AFFIMED N.V. | Director Técnico/Científico/I+D | 22/05/2019 |
CT Atlantic Ltd.
 CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Fundador | 01/12/2014 |
U3 Pharma AG
 U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Fundador | 01/10/2008 |
Formación de Martin Treder.
| Technische Universität München | Doctorate Degree |
| Monash University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| AFFIMED N.V. | Health Technology |
| Empresas privadas | 3 |
|---|---|
CT Atlantic Ltd.
CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Commercial Services |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Commercial Services |
LTZ Therapeutics, Inc.
LTZ Therapeutics, Inc. BiotechnologyHealth Technology LTZ Therapeutics, Inc. is an American immunotherapy-focused biotech company that develops novel therapies. The company was founded by Jianhui Zhou, Robert Li, and Martin Treder, with Robert Li serving as the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Martin Treder